SCHEMBL5771317

SCHEMBL5771317

CC(=O)[C@@H]1CCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2321562 1.00
SCHEMBL890174 1.00
Bromide SCHEMBL6143076 0.98
Bromide SCHEMBL6143081 0.98
Hydrochloric Acid SCHEMBL6147870 0.98
SCHEMBL18731092 0.93
SCHEMBL10367186 0.93
SCHEMBL17928477 0.87
SCHEMBL6143108 0.79 NOS2 (0.52)
SCHEMBL6143295 0.79 NOS2 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3818059-B1 INTERMEDIATES IN THE SYNTHESIS OF C3-SUBSTITUTED CEPHALOSPORINS NORBROOK LAB LTD (GB) 2024-05-22 EP disclosed
WO-2024026481-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
US-11840544-B2 Intermediates in the synthesis of C3-substituted cephalosporins NORBROOK LABORATORIES LIMITED (GB) 2023-12-12 US disclosed
US-11840544-B2 Intermediates in the synthesis of C3-substituted cephalosporins NORBROOK LABORATORIES LIMITED (GB) 2023-12-12 US disclosed
US-11840544-B2 Intermediates in the synthesis of C3-substituted cephalosporins NORBROOK LABORATORIES LIMITED (GB) 2023-12-12 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
WO-2023137113-A2 CHEMICALLY REVERSIBLE 2´-OH ACYLATION PROTECTS RNA FROM HYDROLYTIC AND ENZYMATIC DEGRADATION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-07-20 WO disclosed
WO-2023083295-A1 ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) 2023-05-19 WO disclosed
WO-2023066292-A1 TRICYCLIC BORONIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海济煜医药科技有限公司 2023-04-27 WO disclosed
US-20230013585-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2023-01-19 US disclosed
US-20070043009-A1 Quinazoline derivatives as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2007-02-22 US disclosed
EP-1339723-B1 PROCESS AND ESTER DERIVATIVES USEFUL FOR PREPARATION OF CEPHALOSPORINS PFIZER PROD INC (US) 2006-03-08 EP disclosed
EP-1318148-B1 Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone SK CORP (KR) 2005-01-12 EP disclosed
US-6841688-B2 Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone SK CORPORATION (KR) 2005-01-11 US disclosed
US-20040267008-A1 Process and ester derivatives useful for preparation of cephalosporins PFIZER INC 2004-12-30 US disclosed
EP-1339723-A1 PROCESS AND ESTER DERIVATIVES USEFUL FOR PREPARATION OF CEPHALOSPORINS Pfizer Products Inc. (US) 2003-09-03 EP disclosed
US-20030114693-A1 Method of preparing optically pure (R) - or (S) - tetrahydrofuranyl ketone SK CORPORATION 2003-06-19 US disclosed
EP-1318148-A1 Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone SK Corporation (KR) 2003-06-11 EP disclosed
US-20020099205-A1 Process and ester derivatives useful for preparation of cephalosporins PFIZER INC. 2002-07-25 US disclosed
WO-2002046199-A1 PROCESS AND ESTER DERIVATIVES USEFUL FOR PREPARATION OF CEPHALOSPORINS PFIZER PRODUCTS INC. (US) 2002-06-13 WO disclosed